Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer

by Blagden, Sarah P.
Published in Front Oncol (2015)

A decade of LARP society

by Blagden, Sarah P., Bayfield, Mark, Bousquet-Antonelli, Cecile
Published in RNA Biol (2021)

New challenges in psycho‐oncology: Using drug development methodology to improve survivorship and supportive care intervention trials

by Howells, Lesley, Hulbert‐Williams, Nicholas J., Blagden, Sarah P.
Published in Psychooncology (2019)

Performance status score: do patients and their oncologists agree?

by Blagden, S P, Charman, S C, Sharples, L D, Magee, L R A, Gilligan, D
Published 2003

The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

by Blagden, S P, Foskett, M A, Fisher, R A, Short, D, Fuller, S, Newlands, E S, Seckl, M J
Published 2002

Controversies around the function of LARP1

by Berman, Andrea J., Thoreen, Carson C., Dedeic, Zinaida, Chettle, James, Roux, Philippe P., Blagden, Sarah P.
Published in RNA Biol (2020)

A Study to Evaluate the Cause of Bone Demineralization in Gynecological Cancer Survivors

by Stavraka, Chara, Maclaran, Kate, Gabra, Hani, Agarwal, Roshan, Ghaem-Maghami, Sadaf, Taylor, Alexandra, Dhillo, Waljit S., Panay, Nick, Blagden, Sarah P.
Published 2013

The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5′TOP sequence

by Lahr, Roni M., Mack, Seshat M., Héroux, Annie, Blagden, Sarah P., Bousquet-Antonelli, Cécile, Deragon, Jean-Marc, Berman, Andrea J.
Published in Nucleic Acids Res (2015)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer

by Rizzuto, Ivana, Stavraka, Chara, Chatterjee, Jayanta, Borley, Jane, Hopkins, Thomas Glass, Gabra, Hani, Ghaem-Maghami, Sadaf, Huson, Les, Blagden, Sarah P.
Published in Int J Gynecol Cancer (2015)

Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells

by Dermit, Maria, Dodel, Martin, Lee, Flora C.Y., Azman, Muhammad S., Schwenzer, Hagen, Jones, J. Louise, Blagden, Sarah P., Ule, Jernej, Mardakheh, Faraz K.
Published in Dev Cell (2020)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

by Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Published 2007

LARP1 isoform expression in human cancer cell lines

by Schwenzer, Hagen, Abdel Mouti, Mai, Neubert, Pia, Morris, Josephine, Stockton, Joanne, Bonham, Sarah, Fellermeyer, Martin, Chettle, James, Fischer, Roman, Beggs, Andrew D., Blagden, Sarah P.
Published in RNA Biol (2020)

The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration

by Burrows, Carla, Abd Latip, Normala, Lam, Sarah-Jane, Carpenter, Lee, Sawicka, Kirsty, Tzolovsky, George, Gabra, Hani, Bushell, Martin, Glover, David M., Willis, Anne E., Blagden, Sarah P.
Published 2010

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

by Lahr, Roni M, Fonseca, Bruno D, Ciotti, Gabrielle E, Al-Ashtal, Hiba A, Jia, Jian-Jun, Niklaus, Marius R, Blagden, Sarah P, Alain, Tommy, Berman, Andrea J
Published in eLife (2017)

An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials

by Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.
Published 2014

LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression

by Mura, M, Hopkins, T G, Michael, T, Abd-Latip, N, Weir, J, Aboagye, E, Mauri, F, Jameson, C, Sturge, J, Gabra, H, Bushell, M, Willis, A E, Curry, E, Blagden, S P
Published in Oncogene (2015)

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

by Blagden, Sarah P., Rizzuto, Ivana, Suppiah, Puvan, O’Shea, Daniel, Patel, Markand, Spiers, Laura, Sukumaran, Ajithkumar, Bharwani, Nishat, Rockall, Andrea, Gabra, Hani, El-Bahrawy, Mona, Wasan, Harpreet, Leonard, Robert, Habib, Nagy, Ghazaly, Essam
Published in Br J Cancer (2018)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

by Blagden, S P, Molife, L R, Seebaran, A, Payne, M, Reid, A H M, Protheroe, A S, Vasist, L S, Williams, D D, Bowen, C, Kathman, S J, Hodge, J P, Dar, M M, de Bono, J S, Middleton, M R
Published 2008

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

by Mak, Gabriel, Soria, Jean-Charles, Blagden, Sarah P., Plummer, Ruth, Fleming, Ronald A., Nebot, Noelia, Zhang, Jianping, Mazumdar, Jolly, Rogan, Debra, Gazzah, Anas, Rizzuto, Ivana, Greystoke, Alastair, Yan, Li, Tolson, Jerry, Auger, Kurt R., Arkenau, Hendrik-Tobias
Published in Br J Cancer (2019)

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

by Blagden, Sarah P., Billingham, Lucinda, Brown, Louise C., Buckland, Sean W., Cooper, Alison M., Ellis, Stephanie, Fisher, Wendy, Hughes, Helen, Keatley, Debbie A., Maignen, Francois M., Morozov, Alex, Navaie, Will, Pearson, Sarah, Shaaban, Abeer, Wydenbach, Kirsty, Kearns, Pamela R.
Published in Br J Cancer (2020)